KR102409017B1 - 리포좀을 이용한 아밀로이드 플라크의 mri 영상화 - Google Patents

리포좀을 이용한 아밀로이드 플라크의 mri 영상화 Download PDF

Info

Publication number
KR102409017B1
KR102409017B1 KR1020177012354A KR20177012354A KR102409017B1 KR 102409017 B1 KR102409017 B1 KR 102409017B1 KR 1020177012354 A KR1020177012354 A KR 1020177012354A KR 20177012354 A KR20177012354 A KR 20177012354A KR 102409017 B1 KR102409017 B1 KR 102409017B1
Authority
KR
South Korea
Prior art keywords
delete delete
phospholipid
aromatic
polymer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177012354A
Other languages
English (en)
Korean (ko)
Other versions
KR20170103748A (ko
Inventor
아난스 애나프라가다
에릭 에이. 타니퓸
마양크 스리바스타바
Original Assignee
텍사스 칠드런스 하스피탈
아난스 애나프라가다
에릭 에이. 타니퓸
마양크 스리바스타바
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 텍사스 칠드런스 하스피탈, 아난스 애나프라가다, 에릭 에이. 타니퓸, 마양크 스리바스타바 filed Critical 텍사스 칠드런스 하스피탈
Publication of KR20170103748A publication Critical patent/KR20170103748A/ko
Application granted granted Critical
Publication of KR102409017B1 publication Critical patent/KR102409017B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177012354A 2014-10-08 2015-10-08 리포좀을 이용한 아밀로이드 플라크의 mri 영상화 Active KR102409017B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462061514P 2014-10-08 2014-10-08
US62/061,514 2014-10-08
US201562111057P 2015-02-02 2015-02-02
US62/111,057 2015-02-02
PCT/US2015/054732 WO2016057812A1 (en) 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes

Publications (2)

Publication Number Publication Date
KR20170103748A KR20170103748A (ko) 2017-09-13
KR102409017B1 true KR102409017B1 (ko) 2022-06-16

Family

ID=55653789

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012354A Active KR102409017B1 (ko) 2014-10-08 2015-10-08 리포좀을 이용한 아밀로이드 플라크의 mri 영상화

Country Status (10)

Country Link
US (4) US9744251B2 (enExample)
EP (3) EP3542828A1 (enExample)
JP (1) JP6505235B2 (enExample)
KR (1) KR102409017B1 (enExample)
CN (1) CN107106708B (enExample)
AU (2) AU2015330824A1 (enExample)
CA (1) CA2963941C (enExample)
ES (2) ES3032054T3 (enExample)
MX (1) MX371295B (enExample)
WO (1) WO2016057812A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801957B2 (en) 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
EP3542828A1 (en) 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes
EP3487545A1 (en) 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
WO2018015549A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
US11052162B2 (en) 2016-09-16 2021-07-06 Texas Children's Hospital Liposomal gadolinium (GD) contrast agent “NMRX” for T1-MRI
EP3548002B1 (en) 2016-11-30 2025-04-30 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
CN116173238A (zh) * 2018-03-29 2023-05-30 微脉管治疗有限公司 用于检测和治疗阿尔茨海默病的组合物及方法
WO2019234243A1 (en) 2018-06-08 2019-12-12 Ac Immune Sa Novel compounds for diagnosis
JP7545393B2 (ja) * 2019-01-24 2024-09-04 アルゼカ バイオサイエンシズ、エルエルシー 誤って折りたたまれたタンパク質を画像化するための機能化リポソーム
CN114341364B (zh) * 2019-07-08 2025-07-18 阿尔兹卡生物科学公司 Tau病理靶向配体
US11614451B2 (en) 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
KR102546470B1 (ko) * 2020-01-29 2023-06-21 텍사스 칠드런스 하스피탈 아밀로이드 침착의 mri용 표적 조영제
WO2021163585A1 (en) 2020-02-12 2021-08-19 Texas Children's Hospital Targeted contrast agents for mri of alpha-synuclein deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
CN115970009A (zh) * 2023-02-08 2023-04-18 丽水市中心医院 Vhpk多肽修饰的荧光纳米脂质体给药系统、其制备方法及应用
CN116869938A (zh) * 2023-07-26 2023-10-13 安徽医科大学 一种1,2,4-噁二唑-吡啶脂质体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031326A1 (en) 2003-05-01 2007-02-08 Neurosurvival Technologies, Ltd. Compounds that selectively bind to membranes of apoptotic cells
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
US20120258044A1 (en) 2011-04-06 2012-10-11 Ananth Annapragada Lipid-based nanoparticles

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
CN1148812A (zh) 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
JP4829454B2 (ja) 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
AU2003217950A1 (en) 2002-03-05 2003-09-22 Cleveland State University Agglomerated particles for aerosol drug delivery
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
WO2006032705A2 (en) 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
WO2007041855A1 (en) 2005-10-13 2007-04-19 Waratah Pharmaceuticals, Inc. Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
WO2007048019A2 (en) 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
WO2008134618A2 (en) 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
CA2695204A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
CA2708028A1 (en) 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
WO2009152445A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JP2012520898A (ja) 2009-03-19 2012-09-10 マーヴァル バイオサイエンシーズ，インコーポレイテッド 画像化におけるコントラスト強調のための組成物および方法
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
ES2526124T3 (es) * 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
AU2012223210B2 (en) 2011-03-02 2016-12-22 Board Of Regents Of The University Of Texas System Vesicle compositions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
AU2014240042C1 (en) * 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
EP3542828A1 (en) 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031326A1 (en) 2003-05-01 2007-02-08 Neurosurvival Technologies, Ltd. Compounds that selectively bind to membranes of apoptotic cells
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
US20120258044A1 (en) 2011-04-06 2012-10-11 Ananth Annapragada Lipid-based nanoparticles

Also Published As

Publication number Publication date
EP3204051B1 (en) 2019-05-29
ES3032054T3 (en) 2025-07-15
CA2963941A1 (en) 2016-04-14
US20170080111A1 (en) 2017-03-23
US10537649B2 (en) 2020-01-21
JP2017532378A (ja) 2017-11-02
US20200179540A1 (en) 2020-06-11
EP4035688C0 (en) 2025-03-26
BR112017007238A2 (pt) 2018-01-16
AU2021203388B2 (en) 2024-05-30
KR20170103748A (ko) 2017-09-13
ES2743704T3 (es) 2020-02-20
HK1243335A1 (zh) 2018-07-13
EP3204051A4 (en) 2018-06-27
EP3204051A1 (en) 2017-08-16
AU2015330824A1 (en) 2017-05-25
EP4035688A1 (en) 2022-08-03
MX2017004695A (es) 2018-01-24
CN107106708B (zh) 2021-06-18
CA2963941C (en) 2023-08-01
AU2021203388A1 (en) 2021-06-24
EP4035688B1 (en) 2025-03-26
MX371295B (es) 2020-01-24
US20160101197A1 (en) 2016-04-14
US20200069820A1 (en) 2020-03-05
CN107106708A (zh) 2017-08-29
US9744251B2 (en) 2017-08-29
US11141495B2 (en) 2021-10-12
EP3542828A1 (en) 2019-09-25
JP6505235B2 (ja) 2019-04-24
WO2016057812A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
US11141495B2 (en) MRI imaging of amyloid plaque using liposomes
Tanifum et al. A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging
Harrison et al. Multimeric near IR–MR contrast agent for multimodal in vivo imaging
KR102035187B1 (ko) 지질-기반 나노입자들
JP7545393B2 (ja) 誤って折りたたまれたタンパク質を画像化するための機能化リポソーム
US10124078B2 (en) Lipid-based nanoparticles
HK40010427A (en) Mri imaging of amyloid plaque using liposomes
BR112017007238B1 (pt) Composição lipossomal compreendendo um conjugado fosfolipídiopolímero-aromático e um agente potencializador de contraste de imagem de ressonância magnética não radioativo para geração de imagem de depósitos amiloides
HK1243335B (en) Mri imaging of amyloid plaque using liposomes
US20230136718A1 (en) Functionalized liposomes for imaging misfolded proteins
Rashid Lanthanide-Based Responsive Contrast Agents for Magnetic Resonance Imaging

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5